An oral preparation of Lactobacillus acidophilus for the treatment of uncomplicated acute watery diarrhoea in Vietnamese children: study protocol for a multicentre, randomised, placebo-controlled trial

Trials

Stephen Baker⁴  H Rogier van Doorn²  Jeremy Farrar²  Nguyen Van Vinh Chau²  Ha Manh Tuan⁶  Tran Thi Ngoc Dung¹  James I Campbell²  Laura Merson¹  Marcel Wolbers²  Corinne Thompson¹  Pham Thi Ngoc Tuyet⁶  Ha Vinh⁵  Marion-Eliëtte Kolader³ 

[1] The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam;Nuffield Department of Clinical Medicine, Oxford University, Oxford, UK;Department of Medical Microbiology, Academic Medical Centre, Amsterdam, the Netherlands;The London School of Hygiene and Tropical Medicine, London, UK;The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam;Children’s Hospital 2, Ho Chi Minh City, Vietnam

关键词: Norovirus;    Rotavirus;    Randomised controlled trial;    Diarrhoea;    Lactobacillus spp.;    Probiotics;   

Others  :  1094880
DOI  :  10.1186/1745-6215-14-27

 received in 2012-07-05, accepted in 2012-12-27,  发布年份 2013

【 摘 要 】

Background

Diarrhoeal disease is a major global health problem, particularly affecting children under the age of 5 years. Besides oral rehydration solution, probiotics are also commonly prescribed to children with acute watery diarrhoea in some settings. Results from randomised clinical trials (RCTs) in which investigators studied the effect of probiotics on diarrhoeal symptoms have largely shown a positive effect; yet, the overall quality of the data is limited. In Vietnam, probiotics are the most frequently prescribed treatment for children hospitalised with acute watery diarrhoea, but there is little justification for this treatment in this location. We have designed a RCT to test the hypothesis that an oral preparation of Lactobacillus acidophilus is superior to placebo in the treatment of acute watery diarrhoea in Vietnamese children.

Methods

This RCT was designed to study the effect of treatment with L. acidophilus (4 × 10⁹ colony-forming units/day) for 5 days for acute watery diarrhoea against a placebo in 300 children ages 9 to 60 months admitted to hospitals in Vietnam. Clinical and laboratory data plus samples will be collected on admission, daily during hospitalisation, at discharge, and at follow-up visits for a subset of participants. The primary end point will be defined as the time from the first dose of study medication to the start of the first 24-hour period without diarrhoea as assessed by the on-duty nurse. Secondary endpoints include the time to cessation of diarrhoea as recorded by parents or guardians in an hourly checklist, stool frequency over the first 3 days, treatment failure, rotavirus and norovirus viral loads, and adverse events.

Discussion

The existing evidence for the use of probiotics in treating acute watery diarrhoea seems to favour their use. However, the size of the effect varies across publications. An array of different probiotic organisms, doses, treatment durations, study populations, designs, settings, and aetiologies have been described. In this trial, we will investigate whether probiotics are beneficial as an adjuvant treatment for children with acute watery diarrhoea in Vietnam, with the aim of guiding clinical practice through improved regional evidence.

Trial registration

Current Controlled Trials ISRCTN88101063

【 授权许可】

   
2013 Kolader et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: Diarrhoeal Disease (Fact Sheet No. 330). Geneva; Author. http://www.who.int/mediacentre/factsheets/fs330/en/index.html webcite
• [2]You D, Jones G, Wardlaw T: Levels & Trends in Child Mortality Report 2011. Estimates Developed by the UN Inter-Agency Group for Child Mortality Estimation (35th edition). New York: United Nations Children’s Fund; 2011:1-–24. http://www.childinfo.org/files/Child_Mortality_Report_2011.pdf webcite
• [3]Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, Mathers C, Black RE, Child Health Epidemiology Reference Group of WHO and UNICEF: Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012, 379(9832):2151-2161.
• [4]Dalby-Payne JR, Elliott EJ: Gastroenteritis in children. Clin Evid (Online) 2011, 7:1-64. pii:0314
• [5]World Health Organization: The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers. 4th rev. ed. Geneva: Author; 2005. http://whqlibdoc.who.int/publications/2005/9241593180.pdf webcite
• [6]Araya M, Morelli L, Reid G, Sanders M, Stanton C: Food and Agriculture Organization of the United Nations and World Health Organization: Guidelines for the Evaluation of Probiotics in Food (Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food). London, ON, Canada; 2002. ftp://ftp.fao.org/es/esn/food/wgreport2.pdf webcite
• [7]Shaukat A, Levitt MD, Taylor BC, MacDonald R, Shamliyan TA, Kane RL, Wilt TJ: Systematic review: effective management strategies for lactose intolerance. Ann Intern Med 2010, 152:797-803.
• [8]McFarland LV: Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 2007, 5:97-105.
• [9]Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JNV, Shanman R, Johnsen B, Shekelle PG: Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012, 307:1959-1969.
• [10]Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH: Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011, 11:CD004827.
• [11]Francavilla R, Lionetti E, Castellaneta S, Ciruzzi F, Indrio F, Masciale A, Fontana C, La Rosa MM, Cavallo L, Francavilla A: Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea: a double-blind study. Aliment Pharmacol Ther 2012, 36:363-369.
• [12]Canani RB, Cirillo P, Terrin G, Cesarano L, Spagnuolo MI, De Vincenzo A, Albano F, Passariello A, De Marco G, Manguso F, Guarino A: Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007, 335(7615):40.
• [13]Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Møller PL, Pedersen P, Tvede M, Weyrehter H, Valerius NH, Paerregaard A: Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J 2002, 21:411-416.
• [14]Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, Kolacek S, Massar K, Micetic-Turk D, Papadopoulou A, De Sousa JS, Sandhu B, Szajewska H, Weizman Z: Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000, 30:54-60.
• [15]Szymański H, Pejcz J, Jawień M, Chmielarczyk A, Strus M, Heczko PB: Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006, 23:247-253.
• [16]Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L: Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997, 25:516-519.
• [17]Fang SB, Lee HC, Hu JJ, Hou SY, Liu HL, Fang HW: Dose-dependent effect of Lactobacillus rhamnosus on quantitative reduction of faecal rotavirus shedding in children. J Trop Pediatr 2009, 55:297-301.
• [18]Sanders ME, Akkermans LMA, Haller D, Hammerman C, Heimbach J, Hörmannsperger G, Huys G, Levy DD, Lutgendorff F, Mack D, Phothirath P, Solano-Aguilar G, Vaughan E: Safety assessment of probiotics for human use. Gut Microbes 2010, 1:164-185.
• [19]Dinleyici EC, Eren M, Ozen M, Yargic ZA, Vandenplas Y: Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther 2012, 12:395-410.
• [20]Allen SJ, Martinez EG, Gregorio GV, Dans LF: Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010, 11:CD003048.
• [21]Sanders ME, Heimbach JT, Pot B, Tancredi DJ, Lenoir-Wijnkoop I, Lähteenmäki-Uutela A, Gueimonde M, Bañares S: Health claims substantiation for probiotic and prebiotic products. Gut Microbes 2011, 2:127-133.
• [22]Rijkers GT, De Vos WM, Brummer RJ, Morelli L, Corthier G, Marteau P: Health benefits and health claims of probiotics: bridging science and marketing. Br J Nutr 2011, 106:1291-1296.
• [23]Yamada K, Sato-Mito N, Nagata J, Umegaki K: Health claim evidence requirements in Japan. J Nutr 2008, 138:1192S-1198S.
• [24]Lewis SJ, Heaton KW: Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997, 32:920-924.
• [25]Dung TT, Phat VV, Nga TV, My PV, Duy PT, Campbell JI, Thuy CT, Hoang NV, Van Minh P, Le Phuc H, Tuyet PT, Vinh H, Kien DT, Huy Hle A, Vinh NT, Nga TT, Hau NT, Chinh NT, Thuong TC, Tuan HM, Simmons C, Farrar JJ, Baker S: The validation and utility of a quantitative one-step multiplex RT real-time PCR targeting rotavirus A and norovirus. J Virol Methods 2013, 187:138-143.
• [26]European Medicines Agency (EMA): ICH Topic E 2 A.Clinical Safety Data Management:Definitions and Standards for Expedited Reporting (Note for Guidance on Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (Cpmp/Ich/377/95)). London: Author; 2006. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002749.pdf webcite
• [27]Collett D: Modelling Survival Data in Medical Research. 2nd edition. Boca Raton, FL: Chapman & Hall/CRC; 2003:209.
• [28]Huys G, Vancanneyt M, D’Haene K, Vankerckhoven V, Goossens H, Swings J: Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. Res Microbiol 2006, 157:803-810.
• [29]Coeuret V, Gueguen M, Vernoux JP: Numbers and strains of lactobacilli in some probiotic products. Int J Food Microbiol 2004, 97:147-156.
• [30]Shane AL, Cabana MD, Vidry S, Merenstein D, Hummelen R, Ellis CL, Heimbach JT, Hempel S, Lynch SV, Sanders ME, Tancredi DJ: Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes 2010, 1:243-253.
• [31]Takanashi S, Hashira S, Matsunaga T, Yoshida A, Shiota T, Tung PG, Khamrin P, Okitsu S, Mizuguchi M, Igarashi T, Ushijima H: Detection, genetic characterization, and quantification of norovirus RNA from sera of children with gastroenteritis. J Clin Virol 2009, 44:161-163.
• [32]Blutt SE, Matson DO, Crawford SE, Staat MA, Azimi P, Bennett BL, Piedra PA, Conner ME: Rotavirus antigenemia in children is associated with viremia. PLoS Med 2007, 4:e121.
• [33]Schrezenmeir J, De Vrese M: Probiotics, prebiotics, and synbiotics: approaching a definition. Am J Clin Nutr 2001, 73(2 Suppl):361S-364S.
• [34]Szymański H, Chmielarczyk A, Strus M, Pejcz J, Jawień M, Kochan P, Heczko PB: Colonisation of the gastrointestinal tract by probiotic L. rhamnosus strains in acute diarrhoea in children. Dig Liver Dis 2006, 38(Suppl 2):S274-S276.
• [35]Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S: Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci 1992, 37:121-128.
• [36]Petschow BW, Figueroa R, Harris CL, Beck LB, Ziegler E, Goldin B: Effects of feeding an infant formula containing Lactobacillus GG on the colonization of the intestine: a dose–response study in healthy infants. J Clin Gastroenterol 2005, 39:786-790.
• [37]Saxelin M, Pessi T, Salminen S: Fecal recovery following oral administration of Lactobacillus strain GG (ATCC 53103) in gelatine capsules to healthy volunteers. Int J Food Microbiol 1995, 25:199-203.
• [38]Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, De Paula JA, Fedorak R, Shanahan F, Sanders ME, Szajewska H, Ramakrishna BS, Karakan T, Kim N, World Gastroenterology Organization: World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012, 46:468-481.
• [39]Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, Dieleman LA, Ringel Y, Guandalini S, Kelly CP, Brandt LJ: Recommendations for probiotic use––2011 update. J Clin Gastroenterol 2011, 45(Suppl):S168-S171.
• [40]Aureli P, Capurso L, Castellazzi AM, Clerici M, Giovannini M, Morelli L, Poli A, Pregliasco F, Salvini F, Zuccotti GV: Probiotics and health: an evidence-based review. Pharmacol Res 2011, 63(5):366-376.
• [41]Shornikova AV, Isolauri E, Burkanova L, Lukovnikova S, Vesikari T: A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhoea. Acta Paediatr 1997, 86(5):460-465.
• [42]Basu S, Paul DK, Ganguly S, Chatterjee M, Chandra PK: Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol 2009, 43:208-213.
• [43]Van Niel CW, Feudtner C, Garrison MM, Christakis DA: Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002, 109:678-684.
• [44]Gareau MG, Sherman PM, Walker WA: Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010, 7:503-514.
• [45]Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D: Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008, 10:37-54.